STAT3 gain-of-function mutations associated with autoimmune lymphoproliferative syndrome like disease deregulate lymphocyte apoptosis and can be targeted by BH3 mimetic compounds

STAT3 gain-of-function mutations associated with autoimmune lymphoproliferative syndrome like disease deregulate lymphocyte apoptosis and can be targeted by BH3 mimetic compounds

Copyright © 2017 Elsevier Inc. All rights reserved.

Détails bibliographiques
Publié dans:Clinical immunology (Orlando, Fla.). - 1999. - 181(2017) vom: 02. Aug., Seite 32-42
Auteur principal: Nabhani, Schafiq (Auteur)
Autres auteurs: Schipp, Cyrill, Miskin, Hagit, Levin, Carina, Postovsky, Sergey, Dujovny, Tal, Koren, Ariel, Harlev, Dan, Bis, Anne-Marie, Auer, Franziska, Keller, Baerbel, Warnatz, Klaus, Gombert, Michael, Ginzel, Sebastian, Borkhardt, Arndt, Stepensky, Polina, Fischer, Ute
Format: Article en ligne
Langue:English
Publié: 2017
Accès à la collection:Clinical immunology (Orlando, Fla.)
Sujets:Journal Article Research Support, Non-U.S. Gov't ABT-737 ALPS Apoptosis BCL-2 BH3-mimetic inhibitor STAT3 Biphenyl Compounds FAS protein, human plus... FASLG protein, human Fas Ligand Protein Nitrophenols Piperazines Proto-Oncogene Proteins c-bcl-2 STAT3 Transcription Factor STAT3 protein, human Sulfonamides fas Receptor Butylated Hydroxytoluene 1P9D0Z171K BH 3 728-39-2
Accès en ligne Volltext